These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38729076)

  • 41. Anti-Gag cytolytic T lymphocytes specific for an alternative translational reading frame-derived epitope and resistance versus susceptibility to retrovirus-induced murine AIDS in F(1) mice.
    Mayrand SM; Healy PA; Torbett BE; Green WR
    Virology; 2000 Jul; 272(2):438-49. PubMed ID: 10873788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
    Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
    Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity.
    Shinozaki Y; Wang S; Miyazaki Y; Miyazaki K; Yamada H; Yoshikai Y; Hara H; Yoshida H
    Int J Cancer; 2009 Mar; 124(6):1372-8. PubMed ID: 19089917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
    Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
    Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
    Yokouchi H; Yamazaki K; Chamoto K; Kikuchi E; Shinagawa N; Oizumi S; Hommura F; Nishimura T; Nishimura M
    Cancer Sci; 2008 Feb; 99(2):361-7. PubMed ID: 18201271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
    Xie Y; Zhang X; Zhao T; Li W; Xiang J
    Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice.
    Zhou H; Tu C; Yang P; Li J; Kepp O; Li H; Zhang L; Zhang L; Zhao Y; Zhang T; Sheng C; Wang J
    Oncoimmunology; 2022; 11(1):2057892. PubMed ID: 35355680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential Immune Modulation With Carbon-Ion Versus Photon Therapy.
    Spina CS; Tsuruoka C; Mao W; Sunaoshi MM; Chaimowitz M; Shang Y; Welch D; Wang YF; Venturini N; Kakinuma S; Drake CG
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):813-818. PubMed ID: 33190969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8
    Li M; Yang Y; Wei J; Cun X; Lu Z; Qiu Y; Zhang Z; He Q
    Nanomedicine; 2018 Nov; 14(8):2541-2550. PubMed ID: 30193815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
    Ke Y; Kapp JA
    J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity].
    Tan XH; Wan YH
    Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):399-403. PubMed ID: 17456382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines.
    Hartmann L; Schröter P; Osen W; Baumann D; Offringa R; Moustafa M; Will R; Debus J; Brons S; Rieken S; Eichmüller SB
    Sci Rep; 2020 Dec; 10(1):21517. PubMed ID: 33299018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
    Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
    Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.
    Xiang J; Huang H; Liu Y
    J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.
    Kato M; Nakamura Y; Suda T; Ozawa Y; Inui N; Seo N; Nagata T; Koide Y; Kalinski P; Nakamura H; Chida K
    Cancer Immunol Immunother; 2011 Jul; 60(7):1029-38. PubMed ID: 21519830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin.
    Wakabayashi A; Nakagawa Y; Shimizu M; Moriya K; Nishiyama Y; Takahashi H
    J Immunol; 2008 Mar; 180(6):4000-10. PubMed ID: 18322209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.